Overview

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Status:
Not yet recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.

Phase:

Phase 4

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel